Association between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients

British Journal of Clinical Pharmacology

Volumn 75, Issue 2, 2013, Pages 522-534

  Xu, Xiaojing ^a   Han, Lifang ^a   Duan, Li ^b   Zhao, Yingchun ^c   Yang, Huaping ^d   Zhou, Boting ^d   Ma, Rui ^e   Yuan, Ruixia ^f   Zhou, Honghao ^a   Liu, Zhaoqian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^f HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

eIF3 ; Nephrotoxicity; Non small cell lung cancer (NSCLC); Ototoxicity; Platinum toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; INITIATION FACTOR 3; INITIATION FACTOR 3ALPHA; IRINOTECAN; NAVELBINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; VOMITING; AGED; CHEMICALLY INDUCED DISORDER; EAR DISEASE; GENETICS; KIDNEY DISEASE; LUNG TUMOR; MIDDLE AGED; MISSENSE MUTATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; EAR DISEASES; EUKARYOTIC INITIATION FACTOR-3; FEMALE; HUMANS; KIDNEY DISEASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE;

MLCS; MLOWN;

EID: 84872222719     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04379.x     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Paz-Ares L, Ross H, O'Brien M, Riviere A, Gatzemeier U, Von Pawel J, Kaukel E, Freitag L, Digel W, Bischoff H, Garcia-Campelo R, Iannotti N, Reiterer P, Bover I, Prendiville J, Eisenfeld AJ, Oldham FB, Bandstra B, Singer JW, Bonomi P. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008; 20: 1608-13.
3. Gadgeel SM, Ruckdeschel JC, Patel BB,Wozniak A, Konski A, Valdivieso M, Hackstock D, Chen W, Belzer K, Burger AM, Marquette L, Turrisi A. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. J Thorac Oncol 2011; 6: 927-33.
4. Clegg A, Scott DA, Hewitson P, Sidhu M,Waugh N. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax 2002; 57: 20-8.
5. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 22: 379-92.
6. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23.
7. Earley JN, Turchi JJ. Interrogation of nucleotide excision repair capacity: impact on platinum-based cancer therapy. Antioxid Redox Signal 2011; 15: 2465-77.
8. Booton R,Ward T, Heighway J, Taylor P, Power F, Ashcroft L, Morris J, Thatcher N. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 2006; 1: 2421-7.
9. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V,Mavroudis D. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009; 10: 118-23.
10. Haybaeck J, O'Connor T, Spilka R, Spizzo G, Ensinger C,Mikuz G, Brunhuber T, Vogetseder A, Theurl I, Salvenmoser W, Draxl H, Banziger R, Bachmann F, Schafer G, Burger M, Obrist P. Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Res 2010; 30: 1047-55.
11. Saletta F, Suryo Rahmanto Y, Richardson DR. The translational regulator eIF3a: the tricky eIF3 subunit! Biochim Biophys Acta 2010; 1806: 275-86.
12. Zhang L, Pan X, Hershey JW. Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J Biol Chem 2007; 23: 5790-800.
13. Dong Z, Liu Z, Cui P, Pincheira R, Yang Y, Liu J, Zhang JT. Role of eIF3a in regulating cell cycle progression. Exp Cell Res 2009; 1: 1889-94.
14. Gong Z, Xu X, Hou R, Guo Y, Sheng F, Ouyang D, Zhou H, Liu Z. Effect of docetaxel on expression of eIF3a in human lung cancer A549 cell line. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010; 35: 771-6.
15. Shen J, Li H, Zhange J, Liu L, Tan Y, Zhou H, Liu Z. Expression of eIF3S10 in lung cancer and its relationship with chemotherapy response. Int J Pathol Clin Med 2006; 26: 110-5.
16. Harris TE, Chi A, Shabanowitz J, Hunt DF, Rhoads RE, Lawrence JC Jr. mTOR-dependent stimulation of the association of eIF4G and eIF3 by insulin. EMBO J 2006; 19: 1659-68.
17. Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, Ye Y, Gu J, Spitz MR,Wu X. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer 2011; 71: 82-8.
18. Olson JE,Wang X, Goode EL, Pankratz VS, Fredericksen ZS, Vierkant RA, Pharoah PD, Cerhan JR, Couch FJ. Variation in genes required for normal mitosis and risk of breast cancer. Breast Cancer Res Treat 2010; 119: 423-30.
19. Alexander SPH,Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 4th Edition. Br J Pharmacol 2009; 158: (Suppl. 1): 1-254.
20. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 2: 205-16.
21. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995; 13: 228-44.
22. Rybak LP, Husain K, Morris C,Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity.Am J Otol 2000; 21: 513-20.
23. Wijnhoven SW, Hoogervorst EM, de Waard H, van der Horst GT, van Steeg H. Tissue specific mutagenic and carcinogenic responses in NER defective mouse models. Mutat Res 2007; 3: 77-94.
24. Caronia D, Patino-Garcia A,Milne RL, Zalacain-Diez M, Pita G, Alonso MR, Moreno LT, Sierrasesumaga-Ariznabarreta L, Benitez J, Gonzalez-Neira A. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 2009; 9: 347-53.
25. Yin JY, Shen J, Dong ZZ, Huang Q, Zhong MZ, Feng DY, Zhou HH, Zhang JT, Liu ZQ. Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair. Clin Cancer Res 2011; 1: 4600-9.
26. Meyer KB,Madias NE. Cisplatin nephrotoxicity.Miner Electrolyte Metab 1994; 20: 201-13.
27. Kuhlmann MK, Burkhardt G, Kohler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 1997; 12: 2478-80.
28. Kroning R, Lichtenstein AK, Nagami GT. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol 2000; 45: 43-9.
29. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice.Am J Physiol Renal Physiol 2005; 289: 166-74.
30. Asp E, Nilsson D, Sunnerhagen P. Fission yeast mitogen-activated protein kinase Sty1 interacts with translation factors. Eukaryot Cell 2008; 7: 328-38.
31. Kim KW, Hwang M, Moretti L, Jaboin JJ, Cha YI, Lu B. Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy 2008; 4: 659-68.
32. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005; 18: 569-80.
33. Gazdar AF. DNA repair and survival in lung cancer-the two faces of Janus. N Engl J Med 2007; 22: 771-3.